Kailera Therapeutics launched one of the biggest biotech IPOs in years, pricing an upsized offering that raised $625 million to fund clinical development of an obesity-focused pipeline licensed from China’s Hengrui Pharma. The company is betting investor demand on its “obesity-first” strategy and a late-stage path led by ribupatide (KAI-9531), a once-weekly GLP-1/GIP dual agonist now in phase III testing. The IPO capital will also support broader clinical work across its injectable and oral obesity drug candidates as Kailera builds out an install base and commercialization readiness. For investors, the deal underscores continued appetite for GLP-1-adjacent mechanisms amid escalating competition and scrutiny around long-term tolerability and outcomes. Kailera’s public debut follows a near-record-setting window for U.S. biopharma offerings, positioning the company to compete on differentiation beyond traditional GLP-1-only approaches. With proceeds earmarked for global trials, the company is effectively buying runway into pivotal readouts and regulatory engagement for its most advanced asset.